COMMUNIQUÉS West-GlobeNewswire

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
31/03/2025
NAARDEN, the Netherlands and MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
ProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024
31/03/2025
Company to Accelerate BE-Smart Commercialization as a Cash-Pay Diagnostic Significantly reduces overhead, improves margins heading into Q2 2025 Company to hold a conference call Monday, March 31, 2025, at 11:00 AM EST [...]
Synergy CHC Reports its Eighth Consecutive Quarter of Profitability and its Fourth Quarter and Full Year 2024 Financial Results
31/03/2025
Appoints Jaime Fickett as Permanent Chief Financial Officer WESTBROOK, Maine, March 31, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and [...]
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
31/03/2025
CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in [...]
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
31/03/2025
WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally [...]
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)
31/03/2025
For the first time, Thompson shares his journey living with gastroesophageal reflux disease (GERD) and experience using VOQUEZNA, as part of the new GERD IS NO JOKE campaign VOQUEZNA is a potassium competitive acid [...]
SAB BIO Reports Full Year 2024 Operating and Financial Results
31/03/2025
SAB-142 Phase 1 trial positive topline data announced at KOL event MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS ), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel [...]
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
31/03/2025
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's [...]
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
31/03/2025
MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025 Raised $140 Million in [...]
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
31/03/2025
Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a [...]
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
31/03/2025
Successful initial administration and full enrollment in first-in-human LIBERATE-1 ™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 Positive NPM-139 ( [...]
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV
31/03/2025
MINNEAPOLIS and BRISBANE, Australia, March 31, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris ® or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, [...]
Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission
31/03/2025
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated [...]
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
31/03/2025
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data [...]
Atavistik Bio Announces Appointment of William Sellers, M.D. to its Scientific Advisory Board
31/03/2025
Dr. William Sellers is a leading cancer researcher who currently serves as a Core Institute member and Director of the cancer program at the Broad Institute and a professor of medicine at Dana-Farber Cancer Institute [...]
Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives
31/03/2025
AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026 Multiple presentations at [...]
Venus Concept Announces Fourth Quarter and Fiscal Year 2024 Financial Results
31/03/2025
TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months [...]
Ocular Therapeutix™ to Participate in Two Investor Conferences in April
31/03/2025
BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will [...]
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
31/03/2025
– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence [...]

Pages